An analysis of the Michaelis-Menten pharmacokinetics of phenytoin in epileptic Indonesian adults
DOI:
https://doi.org/10.46542/pe.2023.234.311315Keywords:
Epilepsy, Michaelis-Menten, Phenytoin, SeizureAbstract
Background: Phenytoin metabolism has been shown to vary in different ethnic groups. Therefore, the authors studied phenytoin pharmacokinetics in Indonesian adult patients with epilepsy.
Objective: The purpose of this study was to determine and analyse the pharmacokinetic parameters of Michaelis Menten Vmax (maximum velocity) and Km (the Michaelis constant) of phenytoin in adult epileptic patients.
Method: Twelve adult epileptic patients were chosen on the basis that they had two reliable steady-state phenytoin serum levels at two different daily doses and they required an additional adjustment of phenytoin dosage monotherapy.
Result: The Vmax and Km values for adult epileptic patients respectively, ranged from 3.78 to 9.65 mg/kg/day and from 0.71 to 5.58 mg/L and there was no correlation with age and weight (p > 0.05). The Vmax and Km values have shown individual variability.
Conclusion: The optimal adjustment of phenytoin dose individually in adult epileptic patients based on Vmax and Km parameters needs to be done to get the desired steady-state level according to the clinical response.
References
Alqahtani, S., Alzaidi, T., Alotaibi, M. & Alsultan, A. (2019). Estimation of Phenytoin Pharmacokinetic Parameter in Saudi Epileptic Patients. Pharmacology, 104(1-2), 60-66. https://doi.org/10.1159/000500314
Bauer, L. (2008). Applied clinical Pharmacokinetic (2nd ed., pp 485-547). McGraw Hill. https://uomustansiriyah.edu.iq/media/lectures/4/4_2019_02_23!03_40_49_PM.pdf
Chanruang, A., Rakhgam, M., Teekachunhatean, S., Daengsueptrakun, K., & Punyawudho, B. (2021). Determination of pharmacokinetic parameters and factors influencing the pharmacokinetic parameters of phenytoin in Thai children with epilepsy. International Journal of Pharmacy and Pharmaceutical Sciences, 13(1), 47-51. http://dx.doi.org/10.22159/ijpps.2021v13i1.37178
Chaudhry, A. S., Urban, T. J., Lamb, J. K., Birnbaum, A. K., Remmel, R. P., Subramanian, M., Strom, S., You, J. H., Kasperaviciute, D., Catarino, C. B., Radtke, R. A., Sisodiya, S. M., Goldstein, D. B., & Schuetz, E. G. (2010). CYP2C9*1B promoter polymorphisms, in linkage with CYP2C19*2, affect phenytoin autoinduction of clearance and maintenance dose. Journal of Pharmacology and Experimental Therapeutics, 332 (2), 599-611. https://doi.org/10.1124/jpet.109.161026
Dagenais, R., Wilby, K., Elewa, H., Ensom, M. (2017). Systematic Review. Impact of genetic polymorphisms on phenytoin pharmacokinetics and clinical outcomes in the Middle East and North Africa region. Drugs in R&D, 17, 341-361. https://doi.org//10.1007/s40268-017-0195-7
Edeki, T. I., Brase, D. A. (1995). Phenytoin disposition an toxicity: Role of pharmacogenetic and interethnic factors. Drug Metabolism Reviews, 27(3), 449-469. https://doi.org/10.3109/03602539508998331
Glauser, T., Shinnar, S., Gloss, D., Alldredge, B., Arya, R., Bainbridge, J., Bare, M., Bleck, T., Dodson, W. E., Garrity, L., Jagoda, A., Lowenstein, D., Pellock, J., Riviello, J., Sloan, E., & Treiman, D. M. (2016). Evidence-based guideline: Treatment of convulsive status epilepticus in children and adults: Report of the guideline committee of American epilepsy society. Epilepsy Currents, 16(1), 48-61. https://doi.org/10.5698/1535-7597-16.1.48
Horn, J. R. (2021). Important drug interactions and their mechanism. In: Katzung, B. G. & Vanderah, T. W. (Eds.), Basic & Clinical Pharmacology (15th ed., 1206-1225). McGraw-Hill Education. https://accessmedicine.mhmedical.com/content.aspx?bookid=2988§ionid=250605675
Ismail, R., Rahman, A. F. A. (1990). Michaelis-Menten pharmacokinetics of phenytoin in adult Malaysian patients. Journal of Clinical Pharmacy and Therapeutics, 15(6), 411-417. https://doi.org/10.1111/j.1365-2710.1990.tb00405.x
Lowenstein, D. H. (2017). Seizures and epilepsy. In: Hauser S. L. (Eds.), Harrison's Neurology in Clinical Medicine (4th ed., 231-235) McGraw-Hill Education. https://neurology.mhmedical.com/content.aspx?bookid=2207§ionid=169222561
Lertsinudom, S., Chaiyakum, A., Tuntapakul, S., Sawanyawisuth, S., & Tiamkao, S. (2014). Therapeutic drug monitoring in Epileptic Clinic. Neurology International, 6(4), 5620. https://doi.org/10.4081/ni.2014.5620
Ozkaynakci, A., Gulcebi, M. I., Ergec, D., Ulucan, K., Uzan, M., Ozkara, C., Guney, B., Onat, F. Y. (2015). The effect of polymorphic metabolism enzym on serum phenytoin level. Neurological Sciences, 36(3), 397-401. https://doi.org/10.1007/s10072-014-1961-8
Rowland, M., & Tozer, T. N. (2020). Clinical pharmacokinetics. Concepts and applications (5th ed.). Wolters Kluwer. https://www.perlego.com/book/3729709/rowland-and-tozers-clinical-pharmacokinetics-and-pharmacodynamics-concepts-and-applications-pdf
Shargel, L., & Yu, A. (2022). Nonlinear pharmacokinetics. In: Shargel, L., & Yu, A. Applied biopharmaceutics & pharmacokinetics (8th ed., 229-373). Mc Graw Hill Education. https://accesspharmacy.mhmedical.com/book.aspx?bookID=3127
Silvado, C. E., Terra, V. C., & Twardowschy, C. A. (2018). Pharmacogenomics research and personalized medicine, 11, 51-58. https://doi.org/10.2147/pgpm.s108113
Suzuki, Y., Mimaki, T., Cox, S., Koepke, J., Hayes, & J., Walson, P. D. (1994). Phenytoin age-dose-concentration relationship in children. Therapeutic Drug Monitoring, 16(2), 145-50. https://doi.org/10.1097/00007691-199404000-00006
Twardowschy, C. A., Werneck, L. C., Scola, R. H., Paola, L. D., & Silvado, C. E. (2011). CYP2C9 polymorphism in patients with epilepsy: Genotypic frequency analyzes and phenytoin adverse reactions correlation. Arquivos de Neuro-Psiquiatria, 69(2A), 153-158. doi: https://doi.org/10.1590/s0004-282x2011000200002
Wu, M., & Lim, W. (2013). Phenytoin: A guide to therapeutic Drug monitoring. Proceedings of Singapore Healthcare, 22(3), 198-202. https://doi.org/10.1177/201010581302200307
